4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, which is authorised and regulated by the Financial Conduct Authority, register number 775193
© 2015-2019 by 4BIO Ventures Management Ltd

4BIO portfolio company Orchard Therapeutics goes public

November 1, 2018

Orchard Therapeutics plc (Nasdaq:ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies, today announced the pricing of its initial public offering in the United States of 14,285,715 American Depositary Shares ("ADSs") representing 14,285,715 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions. In addition, Orchard has granted the underwriters a 30-day option to purchase up to an additional 2,142,857 ADSs at the initial public offering price, less the underwriting discounts and commissions. Orchard's ADSs are expected to begin trading on The Nasdaq Global Select Market on October 31, 2018, under the ticker symbol "ORTX." Each of the ADSs are being offered by Orchard. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Orchard, are expected to be $200.00 million, excluding any exercise of the underwriters' option to purchase additional ADSs. The offering is expected to close on November 2, 2018, subject to the satisfaction of customary closing conditions. Read more at Globe Newswire.

Please reload

ARCHIVE
Please reload

SEARCH BY TAGS
Please reload

FOLLOW US